MedTrace Logo

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC

NCT02492568 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-08-17

No results posted yet for this study

Summary

To evaluate the increase in Overall Response Rate (ORR) in the pembrolizumab alone arm compared to the pembrolizumab after SBRT arm at 12 weeks

Conditions

Interventions

DRUG

pembrolizumab

RADIATION

Stereotactic Body Radiation Therapy

Sponsors & Collaborators

Principal Investigators

  • Paul Baas, MD, PhD · Antoni van Leeuwenhoek

  • Willemijn Theelen, MD · Antoni van Leeuwenhoek

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02492568 on ClinicalTrials.gov